Distribution of antibodies specific to the 19-kDa and 33-kDa fragments of Plasmodium vivax merozoite surface protein 1 in two pathogenic strains infecting Korean vivax malaria patients
Plasmodium vivax merozoite surface protein 1 (PvMSP1) is the most intensively studied malaria vaccine candidate. Although high antibody response-inducing two C-terminal fragments of PvMSP1 (PvMSP1-19 and PvMSP1-42) are currently being developed as candidate malaria vaccine antigens, their high genetic diversity in various isolates is a major hurdle. The sequence polymorphism of PvMSP1 has been investigated; however, the humoral immune responses induced by different portions of this protein have not been evaluated in the Republic of Korea.
Source: Osong Public Health and Research Perspectives - Category: Global & Universal Authors: Sylvatrie-Danne Dinzouna-Boutamba, Sanghyun Lee, Ui-Han Son, Su-Min Song, Hye Soo Yun, So-Young Joo, Dongmi Kwak, Man Hee Rhee, Dong-Il Chung, Yeonchul Hong, Youn-Kyoung Goo Tags: Original Article Source Type: research
More News: Genetics | Health | International Medicine & Public Health | Malaria | Malaria Vaccine | Vaccines